Crescent Biopharma, Inc.
Crescent Biopharma, Inc. (Nasdaq: CBIO) is a clinical-stage biotechnology company developing antibody therapies for cancer. Its portfolio centers on CR-001, a bispecific antibody designed to target both PD-1 and VEGF, and antibody-drug conjugates (ADCs) that deliver cancer-killing payloads to tumor cells. The company… From the company’s description.
In fiscal 2025, Crescent Biopharma, Inc. reported revenue of $10.84M and a net loss of $153.94M. Operations used $71.53M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Crescent Biopharma, Inc. does
In the company’s own words
Crescent Biopharma, Inc. (Nasdaq: CBIO) is a clinical-stage biotechnology company developing antibody therapies for cancer. Its portfolio centers on CR-001, a bispecific antibody designed to target both PD-1 and VEGF, and antibody-drug conjugates (ADCs) that deliver cancer-killing payloads to tumor cells. The company plans to develop these candidates as standalone treatments and in combinations, including CR-001 with ADCs. Its lead program, CR-001, entered a global Phase 1/2 trial in 2026 for multiple solid tumors; its ADC candidates include CR-002, which targets PD-L1, and CR-003, which targets integrin beta-6. Crescent’s development priorities include thoracic, gastrointestinal and gynecologic cancers, among other solid tumors. The company has no reportable business segments described in its business overview. Crescent was formerly GlycoMimetics and became Crescent Biopharma through a 2025 reverse recapitalization with a private company established in 2024. Its website is https://crescentbiopharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1253689
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Crescent Biopharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Crescent Biopharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Crescent Biopharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Crescent Biopharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Crescent Biopharma, Inc.'s last four quarterly filings that the numbers alone won't show?”